Video

'Mixed Bag': Only a Fraction of Recent Drug Approvals in NSCLC Space 'Considered Practice Changing'

The recent surge of drug approvals in the non-small cell lung cancer (NSCLC) space by the Food and Drug Administration (FDA) is quite unusual and only a fraction of them are considered practice changing, according to Dr. Timothy Burns.

The recent surge of drug approvals in the non-small cell lung cancer (NSCLC) space by the Food and Drug Administration (FDA) is quite unusual — and only a fraction of them are considered practice-changing, according to Dr. Timothy Burns.

“Some of them are a little head scratching based on the standards that have been used in the past and some of them are, you know, the real deal; we're quite excited about,” Burns, a medical oncologist at UPMC Hillman Cancer Center, said in a recent interview with CURE®. “So, it's kind of a mixed bag.”

Transcript:

CURE®: By all counts, the FDA approved seven therapies to treat non-small cell lung cancer back in May. How surprising is it to see so many therapies in one disease state-approved in one month?

It's unusual, and I'd say a fraction of them are actually practice changing. So, you know, some of them are a little head-scratching based on the standards that have been used in the past and some of them are, you know, the real deal; we're quite excited about. So, it's kind of a mixed bag. You know, we can kind of go through some of them, as well as I don't know if you want to talk about the ADAURA trial, which hasn't been FDA approved, but likely will be soon. That's when using an EGFR TKI in the adjuvant setting, that's probably the most practice-changing thing that's come out this year. And for whatever reason, the FDA, despite approving a lot of kind of "me too" type drugs, is not approved yet, but I think will shortly.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.